As usual, I agree with your thinking. 113 is the product of the same targeted molecular design as Ponatinib was, and therefore it is not unreasonable to anticipate similar results in terms of efficacy and safety. Certainly the institutions have bet heavily including some extremely astute players like Soros and the Baker brothers. Far be it from this humble retailer to bet against them. I think the last couple of days represent a slight correction to an overheated market and sector. We are holding our own relative to other biotechs and personally I am not concerned as we have much to look forward to.
News 
Market Data 
Discover 
